Events

In this webinar, William Hope will talk about the role of pharmacokinetics and pharmacodynamics for antimicrobial drug development. He will discuss the EMA guideline on the use of PK/PD and basic studies to inform dose finding strategies. He will also advise on realistic benchmarking, endpoints, and interpretation of study results.

Facilitating Payment Reform Pathways for Antimicrobial Drugs through FDA and CMS Collaboration As you know, the rise in antimicrobial resistant infections is a major public health threat. Few treatment options […]

The Food and Drug Administration is holding a public workshop entitled “Development of Non-Traditional Therapies for Bacterial Infections." The purpose of the public workshop is to discuss the general development […]

Today, many innovators in the diagnostics industry struggle for funding, and yet news of large scale acquisitions or large (over $30M) funding rounds pops up regularly. How can innovators better […]

Kevin Outterson to present

There are 453K new C. difficile infections (CDI) every year and 83K recurrent infections, yet there are no licensed vaccines against this important nosocomial pathogen. The current pipeline of clinical-stage […]

Part 2: Development of antibacterial drugs targeting specific pathogens The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches (Tiers A and B), best suited for more broad-spectrum products, […]

At least 2 million Americans a year contract an antibiotic-resistant infection, the Centers for Disease Control and Prevention reports. So, what can the U.S. do to safeguard public health amid the growing threat of these superbugs? Tune in to a live webcast as Dr. Scott Gottlieb, commissioner of the U.S. Food and Drug Administration, announces […]

The AMR Challenge encourages global leaders to make formal commitments that further progress against antimicrobial resistance. Your efforts could contribute to solutions that protect humans, animals, and the environment from this global threat. The first batch of commitments will be unveiled at a United Nations (UN) General Assembly side event on September 25, and will […]

Helping Antibacterial Development to Move Forward - New discovery platforms, novel screens and approaches are vital for the discovery of new antibacterials and for ceasing the dangerous trend of multidrug microbial resistance. Cambridge Healthtech Institute's 5th Annual Antibacterial Discovery and Development track will focus on the general, strategic issues and solutions that would allow new […]